AG
AVIR icon

Algert Global’s Atea Pharmaceuticals AVIR Stock Holding History

Algert Global’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$179K Buy
+38,520
New +$192K ﹤0.01% 1196
2025
Q4 		– Sell
-28,199
Closed -$81.8K – 1142
2025
Q3 		$81.8K Sell
28,199
-2,440
-8% -$8.33K ﹤0.01% 1095
2025
Q2 		$110K Hold
30,639
– – ﹤0.01% 1134
2025
Q1 		$91.6K Buy
30,639
+3,240
+12% +$10.1K ﹤0.01% 1133
2024
Q4 		$91.8K Hold
27,399
– – ﹤0.01% 1123
2024
Q3 		$91.8K Buy
27,399
+3,102
+13% +$11.2K ﹤0.01% 1122
2024
Q2 		$80.4K Buy
24,297
+1,237
+5% +$4.61K ﹤0.01% 1414
2024
Q1 		$93.2K Sell
23,060
-13,840
-38% -$54.2K ﹤0.01% 1016
2023
Q4 		$113K Sell
36,900
-13,610
-27% -$41.2K ﹤0.01% 1061
2023
Q3 		$152K Buy
50,510
+2,230
+5% +$7.59K 0.01% 993
2023
Q2 		$181K Buy
48,280
+24,039
+99% +$90K 0.01% 997
2023
Q1 		$81.2K Buy
24,241
+2,617
+12% +$10.6K ﹤0.01% 1092
2022
Q4 		$104K Hold
21,624
– – 0.01% 1069
2022
Q3 		$123K Sell
21,624
-3,832
-15% -$29.3K 0.01% 1090
2022
Q2 		$181K Buy
+25,456
New +$174K 0.01% 1041

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Algert Global's AVIR Position: Q2 2026 in Review

Algert Global opened a new position in Atea Pharmaceuticals (AVIR) in Q2 2026: 38,520 shares worth $179K. The stake represents ﹤0.01% of the portfolio and ranks #1196 among its holdings. This is a return to the name: Algert Global previously reported a position in AVIR as recently as Q3 2025.

Algert Global first reported a position in AVIR in Q2 2022 and has held it in 15 quarters since. The position peaked at $181K in Q2 2022. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Algert Global held 38,520 shares of Atea Pharmaceuticals worth $179K as of Q2 2026.
  • Atea Pharmaceuticals was a new Algert Global position in Q2 2026.
  • Atea Pharmaceuticals made up ﹤0.01% of Algert Global's portfolio in Q2 2026, its #1196 holding.
  • Algert Global first reported a position in Atea Pharmaceuticals in Q2 2022 and has held it in 15 quarters since.
  • Algert Global's Atea Pharmaceuticals position peaked at $181K in Q2 2022.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.